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The widespread influence of miRNAs in many biological processes and 
characteristic changes in expression profiles make them potential biomarkers for 
a range of diseases. With recent discoveries highlighting the enrichment of 
particular circulating miRNAs in plasma under pathological conditions, there has 
been a push for technological advances in miRNA profiling studies as a 
diagnostic tool. 
A standardized, automated, high-throughput method for miRNA isolation 
from human plasma samples was developed in this study. Samples were subject 
to full miRNome profiling utilizing RT-qPCR. These unique findings demonstrate 
that developing a distinct miRNA biomarker profile for heart failure patients is 
feasible and holds potential diagnostic value. 
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1.1 OVERVIEW AND CLINICAL SIGNIFICANCE 
Heart failure (HF) is the leading cause of mortality in industrialized 
countries [26]. HF is the outcome of various myocardial or vascular diseases that 
ultimately result in insufficient cardiac output to maintain blood circulation 
throughout the body [2,26,50]. Various congenital and acquired cardiovascular or 
metabolic diseases such as coronary artery disease, hypertension, and 
myocardial infarction can lead to the structural and functional impairment of the 
heart and development of HF [15,20]. HF cannot be determined with a single test 
[23,31,44]. HF diagnoses are determined collectively by the detection of several 
clinical symptoms confirmed by imaging and circulating levels of various 
neurohormones, which includes the routine assessment of BNP/NT-proBNP 
plasma levels [31,43,37,49]. While the assessment of BNP/NT-proBNP plasma 
levels as a biomarker for HF diagnoses has significantly improved HF disease 
management, several complex factors such as obesity and renal function can 
affect the accuracy of BNP/NT-proBNP as diagnostic tests [8,13,43,38]. This has 
fueled interest in other possible HF biomarkers such as miRNAs. 
MicroRNAs (miRNA) are small noncoding RNAs, approximately 22 
nucleotides long, that post-transcriptionally regulate the expression of various 
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genes by binding to specific messenger RNA (mRNA) transcripts to signal its 
degradation or inhibition before translation into a protein [17,35]. One miRNA 
may regulate 100s-1000s of mRNAs, often in the same biological pathway 
[27,39]. miRNA may act as either positive or negative regulators in various 
specific signaling cascades or cell mechanisms [35,32]. So far, over 1000 human 
miRNA sequences have been listed in miRBase (http://www.mirbase.org), the 
definitive repository of identified miRNA sequences and nomenclature system 
[16,24,32,35]. miRBase is an essential resource for miRNA profiling to include 
pre-cursor and mature miRNAs. 
The mechanism of producing mature miRNAs has been well characterized 
and should be considered when studying these sequences [32,35,44,49]. The 
processing of mature miRNA begins with long primary miRNAs (pri-miRNAs) 
transcripts, which are generally several thousand nucleotides long. Pri-miRNAs 
then undergo several cleavage steps within the nucleus by the Drosha complex 
that result in several pre-miRNA (precursor miRNA). Pre-miRNA sequences are 
hairpin structures, approximately 70-100 nucleotides long. Pre-miRNA is then 
exported out of the nucleus by Exportin [22]. In the cytoplasm, pre-miRNAs are 
further modified/cleaved into several distinct mature miRNA sequences by the 
Dicer protein and loaded onto the RISC complex where they are bound by 
Argonaute. The RISC complex targets mRNA transcripts for inhibition within the 
cell [3,22,28] miRNAs can also be exported outside of the cell during this 
process; however, the exact mechanisms remain unknown [26,45,47]. Recent 
studies have highlighted the presence of miRNAs in plasma.  While miRNAs can 
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exist freely in plasma, endogenous plasma miRNAs are normally packaged in 
lipoproteins, exosomes, or associated with other protein complexes such 
Argonaute [4,19,32,45,47]. 
 The widespread influence of miRNAs in many biological processes and 
characteristic changes in expression profiles make them potential biomarkers for 
a range of diseases including cancer, cardiovascular diseases, metabolic 
diseases, autoimmune diseases, and more [29,32,36,40]. Recent studies have 
highlighted the enrichment of particular circulating miRNAs in plasma under 
pathological conditions [32]. These recent discoveries in miRNA expression have 
pushed for technological advances in miRNA profiling studies as a diagnostic 
tool. 
1.2 CURRENT METHODS AND LIMITATIONS 
The role of miRNAs in cardiac function in the myocardium has been widely 
studied and defined in animal models [2,26,44]. For example, muscle specific 
miR-1, muscle specific miR-133a/b, heart specific miR-208a/b, and heart specific 
miR-499 contribute to myocardial function and are key regulators of cardiac 
hypertrophy [2,5,6]. Classes of miRNAs have been profiled in human studies; 
however, heart tissues and circulating miRNA abundance changes were not 
acquired simultaneously as this is not clinically feasible [44,49]. Due to several 
confounding limitations and conflicting reports, these present studies do not yet 
provide sufficient support for the clinical use of miRNAs or provide a distinct HF 
miRNA profile [14,44,48,49].  
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In the aforementioned human studies, various liquid biopsy sample types 
such as blood, plasma, and serum were used.  Additionally, variability resulted 
from different miRNA isolation methods. Currently miRNA can be isolated from 
cells, fresh tissues, formalin fixed tissues, plasma, serum, and other body fluids 
[1]. Several commercial systems are available for manual miRNA isolation based 
chemical extraction using concentrated chaotropic agents, such as guanidine 
thiocyanate, along with phenol-chloroform followed by solid-phase extraction on 
silica columns [36]. With normal high-quality miRNA yield from cells and tissues, 
circulating miRNA exist in lower concentrations in comparison to normal high-
quality miRNA yield from cells and tissues. This presents a challenge for the 
researcher [28,41]. The previously mentioned methods largely target freely 
circulating miRNA. However, endogenous plasma miRNAs are normally 
associated with vesicles, exosomes, and other protein complexes [19,36,44,51]. 
Current manual exosome isolation methods consist of ultracentrifugation 
or novel exosome affinity based methods [12]. Bound exosomes can then be 
lysed and miRNA isolation methods carried out. The high concentration of 
proteins in plasma and different sample processing conditions could greatly alter 
miRNA content and profiles during isolation methods [25,36,42,44]. For these 
reasons, consistently efficient methods for miRNA extraction from a large number 
of liquid biopsy samples remain deficient. As a result, many reported studies 
have relatively small patient numbers in various HF groups [2,26,44,49]. 
Therefore, there is a significant need to optimize and develop more automated, 
high-throughput methods for miRNA isolation from human liquid biopsies.  
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Additionally, there are several techniques used to measure miRNAs to 
include RNA sequencing, microarrays, and RT-qPCR [26,36,44]. RT-qPCR is the 
most well established procedure. Using these methods, different normalization 
methods and reference genes are reported [25,34,36.44]. Currently, no 
standardized normalization method for miRNA profiling in liquid biopsies exist. As 
emerging technologies have only recently become available, not all studies 
started with a large miRNA panel screen to identify the most differentially 
expressed miRNAs [36]. Consequently, there is a significant need to standardize 
miRNA profiling methods for human liquid biopsies with an unbiased approach. 
Finally, liquid biopsies are used in a wide range of clinical tests due to 
noninvasiveness and easy procurement. However, different pathophysiological 
states could limit biopsy volume and quality. Therefore, using the smallest 
volume possible for miRNA profiling from the patient is of great importance. 
1.3 PROJECT SCOPE/SPECIFIC AIMS 
The overall goal of this study will be to develop for the first time a 
standardized, automated, high-throughput miRNA isolation method from a limited 
amount of plasma for the first time. The fundamental hypothesis of this project is 
that a specific and differential plasma miRNA biomarker profile will be identified 
in heart failure (HF) patients after successfully extracting miRNA using this 
platform.          
 Specific Aim 1: Isolate freely circulating miRNA using the fully automated 
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platform from archived human plasma samples (n=3). miRNA extraction 
efficiency and reproducibility will be validated.  
Specific Aim 2: Identify distinct plasma miRNA profiles in a relevant clinical 
HF study to be utilized as a predictive model for biomarker profiling. Using 
referent control (non-HF) patient samples(n=3) and HF patient samples(n=3), 
gene expression analyses will be carried out by subjecting isolated miRNA to 
real-time qPCR arrays that profile the full known human miRNA genome.  
Using precise measurements and a suitable patient sample size, results 
from this project can be translated into relevant disease diagnostic or prognostic 




ASSESMENT OF AUTOMATED MIRNA ISOLATION
2.1 METHODS 
miRNA isolation. Patient blood samples (referent control: n=3, heart 
failure: n=3) were collected in EDTA blood collection tubes. They were 
immediately centrifuged and plasma was stored at −80 °C in 200 μL aliquots until 
use.  
Total RNA was isolated from 200 μL of plasma. 200 μL plasma samples 
were pre-treated with a phenol-chloroform phase separation. During the pre-
treatment separation, samples were spiked with a known amount of synthetic C. 
elegans miR-39-3p sequence (Cat #219610, Qiagen). The obtained aqueous 
phases of the lysates were transferred to a 2 ml microcentrifuge tube in 
preparation for automated miRNA extraction. miRNA from pre-treated samples 
were further isolated using an automated protocol on the QIAcube workstation 
(Model #9001292, Qiagen) utilizing the miRNeasy Mini Kit (Cat #217004, 
Qiagen). Isolated miRNA was eluted in 20 μL elution buffer.
RT-qPCR. Isolated miRNA was reverse transcribed into a 20 μL cDNA 
using miScript II RT kit (Cat#218161, Qiagen) with incubation at 37οC for 60 min 
and 95οC for 5 min.  cDNA synthesis is shown in Figure 2.1. cDNA was initially 
diluted 10-fold. The diluted cDNA was then serially diluted, and each dilution was 
  
8 
then separately combined with miScript SYBR Green PCR components 
(Cat#218073, Qiagen) which contains the C. elegans mir-39-3p primer for a total 
of 20 μl PCR reaction mix per well.  These reaction mixtures were aliquoted in 
triplicates into predetermined wells of the Rotor-Disc 100. All cDNA synthesis 
steps and PCR setup were performed by the QIAgility (Model #9001532, Qiagen) 
using an automated pipetting protocol. Real-time qPCR was performed on the 
Rotor-Disc 100 by the Rotor-Gene Q real-time PCR cycler (Model #9001570, 
Qiagen). RT-qPCR workflow is shown in Figure 2.2. Rotor-Gene PCR cycling 
conditions were performed according to manufacturer’s suggested protocol and 
conditions: Activation step-15min @ 95οC; 3-step cycling for 40 total cycles: 
denaturation- 15s @ 94οC, annealing- 30s @ 55οC, extension 30s @ 70οC; 
followed by a dissociation (melt) curve analysis. A Cel-miR-39 standard curve 
was generated based on the dilution series. qPCR efficiency was calculated 
using the formula: Efficiency=10(-1/slope)-1.  
2.2 RESULTS 
RT-qPCR. qPCR analysis showed that cel-miR-39-3p exhibited excellent 
linearity between the target input and measured values in a dynamic range of 
1x103 to 1x106 copies/μL of input. Furthermore, in this dynamic range, qPCR 
displayed an estimated 105% PCR efficiency and R2 values that were close to 1 
(0.96–0.99).  A representative standard curve is shown in Figure 2.3. 
 Based on cel-miR-39-3p Ct values, coefficient of variation(CV) values 
were determined to be intraplate:0.62% ± 0.17% and interplate: 1.95% ± 0.43% 




































ASSESMENT OF AUTOMATED MIRNA PROFILING 
3.1 METHODS  
Isolated miRNA was reverse transcribed and RT-qPCR was performed as 
described previously in section 2.2. Entire human miRNA genome (miRNome) 
profiling was performed with Human miRNome miScript miRNA PCR Array 
(Cat#MIHS-113ZR, Qiagen) that analyzes the expression of the 1008 best 
defined and most abundant miRNAs in the human miRNA. Specific pathway-
focused profiling was performed on the Human Cardiovascular Disease miScript 
miRNA PCR Array (Cat#MIHS-113ZR, Qiagen) that analyzes 84 miRNAs 
identified as exhibiting altered expression during cardiovascular disease and 
development. Cel-miR-39-3p was used to normalize miRNAs levels using the  
2-ΔΔCt method. Data analysis was performed in the GeneGlobe Data Analysis 
Center PCR software (Qiagen).  
3.2 RESULTS 
There was detectable expression for approximately 88.89% of the 84 
miRNAs included in the Human Cardiovascular Disease miScript miRNA PCR 
Array. Approximately 80% of miRNA sequences on this panel had a CV of <5% 
as shown in Figure 3.1. The distribution of threshold cycling (Ct) values is shown 




There was detectable expression for approximately 32.23% of the 1008 
miRNAs included in the miRNome miScript miRNA PCR Array. The distribution 
of threshold cycling (Ct) values is shown in Figure 3.3. Distribution of fold change 
values are represented in Table 3.2.  
All PCR array PPC values were in range and indicate high quality RNA 
samples. Furthermore, miRTC values were within range and indicate no 
inhibition of the reverse-transcription reactions. 
Figure 3.4 shows an emerging distinct miRNA profile of samples tested in 
this study. Specified functional groups are described by the Cardiovascular 
Disease miRNA PCR Array which delineates distinct patterns of miRNA 
expression that correlate with specific cardiovascular disorders. These described 
patterns are based on studies involving a broad set of cardiovascular disease 




Table 3.1: Human Cardiovascular miRNA PCR Array - Fold Change 
Distribution 
   
Fold Change 
2-4(n=5) 4-10 (n=33) >10 (n=26) 
hsa-miR-143-3p hsa-miR-93-5p hsa-miR-221-3p 
hsa-miR-16-5p hsa-miR-29b-3p hsa-miR-210-3p 
hsa-miR-22-3p hsa-miR-486-5p hsa-miR-30d-5p 
hsa-miR-206 hsa-miR-25-3p hsa-miR-23a-3p 
hsa-miR-451a hsa-miR-145-5p hsa-miR-183-5p  
hsa-miR-17-5p hsa-miR-125a-5p  
hsa-miR-27a-3p hsa-let-7a-5p  
hsa-miR-30e-5p hsa-miR-26b-5p  
hsa-miR-223-3p hsa-miR-15b-5p  
hsa-miR-342-3p hsa-miR-126-3p  
hsa-miR-100-5p hsa-miR-222-3p  
hsa-miR-208a-3p hsa-miR-224-5p  
hsa-miR-31-5p hsa-miR-146a-5p  
hsa-miR-328-3p hsa-miR-21-5p  
hsa-miR-378a-3p hsa-let-7e-5p  
hsa-miR-494-3p hsa-miR-103a-3p  
hsa-miR-92a-3p hsa-miR-98-5p  
hsa-miR-27b-3p hsa-miR-181b-5p  
hsa-miR-150-5p hsa-miR-23b-3p  
hsa-miR-199a-5p hsa-miR-26a-5p  
hsa-miR-7-5p hsa-let-7d-5p  
hsa-miR-142-3p hsa-miR-30c-5p  
hsa-miR-24-3p hsa-miR-181a-5p  
hsa-miR-130a-3p hsa-miR-107  





















Table 3.2: Human miRNome PCR Array - Fold Change Distribution 
 
Fold Change 
0.5(n=4) 2-4(n=111) 4-10 (n=88) >10 (n=53) 
hsa-miR-193a-5p hsa-miR-125b-5p hsa-let-7a-3p hsa-miR-181a-5p 
hsa-miR-581 hsa-miR-374b-3p hsa-miR-1-3p hsa-miR-181c-5p 
hsa-miR-608 hsa-miR-532-5p hsa-miR-628-3p hsa-miR-423-5p 
hsa-miR-365b-3p hsa-miR-1255b-5p hsa-miR-27b-5p hsa-miR-24-3p  
hsa-miR-3664-5p hsa-miR-25-3p hsa-miR-26b-5p  
hsa-miR-4296 hsa-miR-421 hsa-miR-17-5p  
hsa-miR-18a-3p hsa-miR-342-5p hsa-miR-181b-5p  
hsa-miR-548t-3p hsa-miR-628-5p hsa-miR-224-5p  
hsa-miR-545-5p hsa-miR-877-3p hsa-miR-1260a  
hsa-miR-3135a hsa-let-7c-5p hsa-miR-425-3p  
hsa-miR-505-5p hsa-miR-221-5p hsa-miR-374a-5p  
hsa-miR-551b-3p hsa-miR-486-5p hsa-miR-200c-3p  
hsa-miR-548i hsa-miR-502-3p hsa-miR-21-5p  
hsa-miR-200b-5p hsa-miR-877-5p hsa-miR-107  
hsa-miR-1908-5p hsa-miR-4286 hsa-miR-222-3p  
hsa-miR-432-5p hsa-miR-30b-3p hsa-miR-30e-3p  
hsa-miR-3655 hsa-miR-16-2-3p hsa-let-7d-3p  
hsa-miR-3157-5p hsa-miR-4309 hsa-miR-340-3p  
hsa-miR-941 hsa-miR-7-5p hsa-miR-18a-5p  
hsa-miR-449c-5p hsa-miR-223-5p hsa-miR-23a-3p  
hsa-miR-29a-5p hsa-miR-409-3p hsa-miR-126-5p  
hsa-miR-29b-2-5p hsa-miR-1260b hsa-miR-23b-3p  
hsa-miR-29b-1-5p hsa-miR-195-5p hsa-miR-1307-3p  
hsa-miR-148a-3p hsa-miR-27a-3p hsa-miR-146b-5p  
hsa-let-7g-3p hsa-miR-150-5p hsa-miR-342-3p  
hsa-miR-676-5p hsa-miR-130b-3p hsa-miR-339-5p  
hsa-miR-210-3p hsa-miR-19b-3p hsa-miR-15b-5p  
hsa-miR-539-5p hsa-miR-451a hsa-miR-221-3p  
hsa-miR-1471 hsa-miR-320b hsa-miR-126-3p  
hsa-miR-187-5p hsa-miR-2110 hsa-let-7g-5p  
hsa-miR-409-5p hsa-miR-15b-3p hsa-miR-146a-5p  
hsa-miR-345-5p hsa-miR-495-3p hsa-miR-130a-3p  
hsa-miR-17-3p hsa-let-7f-5p hsa-let-7d-5p  
hsa-miR-1909-5p hsa-miR-22-5p hsa-miR-103a-3p  





0.5(n=4) 2-4(n=111) 4-10 (n=88) >10 (n=53)  
hsa-miR-33b-5p hsa-miR-92a-3p hsa-miR-425-5p  
hsa-miR-4302 hsa-miR-186-5p hsa-miR-148b-3p  
hsa-miR-486-3p hsa-miR-424-5p hsa-miR-139-5p  
hsa-miR-500a-3p hsa-miR-28-3p hsa-miR-145-5p  
hsa-miR-30a-3p hsa-miR-324-3p hsa-miR-30c-5p  
hsa-miR-550a-5p hsa-miR-3907 hsa-miR-144-5p  
hsa-miR-627-5p hsa-let-7i-5p hsa-miR-331-3p  
hsa-miR-192-5p hsa-miR-4291 hsa-miR-151a-5p  
hsa-miR-3182 hsa-miR-223-3p hsa-miR-151a-3p  
hsa-miR-3184-5p hsa-miR-30e-5p hsa-miR-142-3p  
hsa-miR-29c-5p hsa-miR-19a-3p hsa-miR-30b-5p  
hsa-miR-296-3p hsa-miR-766-3p hsa-miR-152-3p  
hsa-miR-1183 hsa-miR-484 hsa-miR-454-3p  
hsa-miR-21-3p hsa-miR-20b-5p hsa-miR-26a-5p  
hsa-miR-99b-3p hsa-miR-197-3p hsa-let-7a-5p  
hsa-miR-380-5p hsa-miR-1280 hsa-miR-664a-3p  
hsa-miR-424-3p hsa-miR-139-3p hsa-miR-4301  



























































































































































































































Figure 3.4: Functional Grouping of miRNAs with >10-fold change. Venn 
diagram shows an emerging distinct miRNA profile study with a >10 fold change 
(HF vs. Referent Control organized by functional groups. miRNAs listed in the 
enlarged bold text were confirmed to have a fold change on both the 
Cardiovascular Disease miRNA PCR Array and the miRNome miScript miRNA 
PCR Array. miRNAs listed in the smaller text only showed a fold change on the 
Cardiovascular Disease miRNA PCR Array, and not the miRNome miScript 






4.1 THESIS CONCLUSION 
 The data gathered from this experiment shows a distinct plasma miRNA 
biomarker profile emerging between heart failure and referent control groups 
after optimizing and implementing a standardized, automated protocol for 
isolating and detecting miRNAs in plasma. With these methods, sample control 
values maintained low CV values to show high reproducibility when comparing 
groups. CV values of individual miRNA sequences were able to be monitored 
and assessed for its performance. These CV values show improvement from 
previous studies done manually. This indicates less user error occurred and 
results were more consistent. While extraction efficiency of samples can be 
improved, the essential outcome is that extraction efficiency remained consistent 
throughout samples. This consistent nature of sample processing further reduces 
variability. 
 Moreover, these automated protocols allowed for higher throughput as 
time and manual steps were decreased. This allowed for the robust testing of a 
select PCR panels and entire miRNome testing. Figure 4.1 shows this 
automated protocol increases time efficiency by a 6:1 ratio when compared to 
corresponding manual protocols. While this study serves as a good basis for 
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future miRNA studies, it also identifies the limitations and areas where 
optimization is needed.
4.2 LIMITATIONS  
 Figure 4.2 identifies the areas of optimization needed to improve this 
protocol and are discussed below. 
Challenge 1:  The initial manual pretreatment step using phenol-
chloroform separation serves as a rate-limiting step in this protocol. Furthermore, 
phenol is a highly corrosive substance and any carryover can have harsh long-
term effects on physical platforms. 
Challenge 2: Endogenous small RNA controls have not been identified in 
plasma samples. The typical snoRNA/snRNA reference genes listed on the PCR 
panel are not recommended for data normalization of plasma/serum studies. 
These snoRNAs/snRNAs have been verified to have relatively invariant 
expression levels across many cell and tissue types; however, many of them 
exist in low and varying amounts in normal plasma/serum samples [7,42]. 
Challenge 3:  qPCR lacks the sensitivity to quantify low abundant plasma 
miRNAs and great variation can be seen in these targets even in the replicates of 
the same sample. While many of the miRNAs were reported with an upregulated 
fold change on the Cardiovascular panel (Table 3.1) also showed the same trend 
on the miRNome panel (Table 3.2), the degree of fold change for some 
sequences varied widely. This is indicative of lack of precision as qPCR is 
heavily relies on indirect measurements and environmental conditions to include 
rate based Ct values and calibration curves. 
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4.3 FUTURE WORK 
 A new PCR technique is emerging that provides solutions to challenges 
#2-3. Droplet digital PCR (ddPCR) allows direct absolute quantification of nucleic 
acids [9,11,46]. This eliminates the need for a reference gene for normalization 
[10,11,19,30].  Furthermore, it is reported that ddpcr is highly sensitive and is 
superior to qPCR when measuring miRNAs in low abundance. This is of high 
importance as miRNAs normally exist in low concentrations in liquid biopsies 
[11,18,30]. Recent studies reported the lowest copy number detected by ddPCR 
was 1 copy per ul of input versus 100 copies per ul of input detected by qPCR in 
the subset of miRNAs tested [30,33].  
A ddPCR proof-of-concept test was done with cel-mir-39.  These 
promising results are displayed in Figure 4.3. In comparison to RT-qPCR, 
ddPCR analysis was less labor intensive. Consequently, ddPCR seems to be the 
future of miRNA quantification and profiling studies.  
 Along with the utilization of ddPCR, increasing sample patient sizes will be 
of utmost importance to determine a distinct miRNA profile for HF patients. Also, 
it is of interest to compare freely circulating miRNA profiles, exosomal miRNA 
profiles, and whole blood profiles in the future.  Of particular interest is whole 
blood collected via PAXgene Blood RNA tubes. PAXgene tubes allows for 
immediate stabilization of blood intracellular RNA to preserve the gene 
expression profile. This could prevent dysregulation of RNA immediately after 
blood is drawn and avoid transferring errors of samples to various tubes such as 
EDTA, serum, etc. 
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This study identifies a standardized, high-throughput protocol that can be 
used as a springboard to optimize miRNA profiling studies to be used as a 













Figure 4.1: Manual Vs Automated Protocol-Time Efficiency. Manual Protocol: 
Actual time shown to process 12 total samples. Automated:  Time shown as 
















Figure 4.2: RT-qPCR Workflow Challenges. Challenging points indicated by 
red circle and red number from top to bottom of workflow. Challenge #1: Manual 
pretreatment. Challenge #2: No endogenous controls for normalization. 








Figure 4.3: ddPCR Proof-of-concept. Image shows representative well count of                      
C-elegans mir-39-3p as a standard. Pink line indicates threshold. Blue dots 
above threshold indicate count of positive droplets that contain at least one 
miRNA copy. Gray dots below threshold indicate count of negative droplets. The 
clustering of negative and positive droplets, respectively, with sufficient 
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